IDEXX Laboratories, Inc. $IDXX Shares Sold by GW&K Investment Management LLC

GW&K Investment Management LLC lowered its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 16.1% during the third quarter, Holdings Channel reports. The fund owned 29,109 shares of the company’s stock after selling 5,572 shares during the quarter. GW&K Investment Management LLC’s holdings in IDEXX Laboratories were worth $18,597,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cresset Asset Management LLC boosted its holdings in IDEXX Laboratories by 18.4% in the third quarter. Cresset Asset Management LLC now owns 4,611 shares of the company’s stock valued at $2,946,000 after purchasing an additional 718 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in shares of IDEXX Laboratories by 7.6% in the 3rd quarter. Victory Capital Management Inc. now owns 198,562 shares of the company’s stock valued at $126,859,000 after buying an additional 13,981 shares during the period. Focus Partners Advisor Solutions LLC lifted its holdings in shares of IDEXX Laboratories by 8.3% in the 3rd quarter. Focus Partners Advisor Solutions LLC now owns 1,140 shares of the company’s stock valued at $790,000 after buying an additional 87 shares during the period. 111 Capital purchased a new stake in shares of IDEXX Laboratories in the third quarter worth about $358,000. Finally, Journey Strategic Wealth LLC grew its holdings in IDEXX Laboratories by 13.7% during the third quarter. Journey Strategic Wealth LLC now owns 540 shares of the company’s stock worth $345,000 after acquiring an additional 65 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of analyst reports. Piper Sandler decreased their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. BTIG Research cut their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. Finally, UBS Group cut their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a report on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $783.33.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total transaction of $920,299.68. Following the sale, the director owned 648 shares of the company’s stock, valued at $407,345.76. The trade was a 69.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Nimrata Hunt sold 2,693 shares of the company’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the sale, the executive vice president directly owned 19,899 shares of the company’s stock, valued at $13,163,984.46. The trade was a 11.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 45,957 shares of company stock worth $29,862,109 in the last ninety days. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Trading Down 4.6%

IDXX stock opened at $618.92 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98. The business’s 50-day moving average is $668.54 and its 200 day moving average is $668.40. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The stock has a market cap of $49.28 billion, a price-to-earnings ratio of 47.35, a PEG ratio of 3.94 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the company earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.